

1 **SUPPLEMENTARY DATA**

2 **Table S1. Clinical characteristics of the patients with SARS-CoV-2 non-structural protein 12 and/or Spike mutations of interest.**

ID	Age	Comorbidity	ICU admission	Mortality	Immunosuppressive treatment	Antiviral treatment	Date of infection	Linage	NSP12	
									Before RDV	After RDV
1	60	Hypertension, enolic dilated myocardopathy	no	no	BNB	RDV 5d	March 2021	Alpha (B.1.1.7)	-	A13535G (Y32C), C14120T (P227L), C15324T
2	68	Hypertension	yes	no	TCZ, CORT	RDV 5d	April 2021	Alpha (B.1.1.7)	C14120T (P227L)	C14120T (P227L), C15324T
3	40	No	no	no	BNB	RDV 5d	March 2021	Alpha (B.1.1.7)	-	G14547A
4	47	No	no	no	TCZ, BNB, CORT	RDV 5d	April 2021	Alpha (B.1.1.7)	A13535G (Y32C), C14120T (P227L), C15324T	G14547A
5	40	No	yes	no	TCZ, BNB, CORT	RDV 5d	April 2021	Delta (B.1.167)	A13535G (Y32C), C14120T (P227L), C15324T	G14547A
6	49	Thalassemia minor	no	no	BNB	RDV 5d	June 2021	Alpha (B.1.1.7)	-	G15652T (D738Y)
7	83	Diffuse large B-cell lymphoma	yes	yes	R-CHOP ^a	LPV + RTV + HCQ 7d, AZM 5d, RDV 10d + 8d, plasma	March – December 2021	Delta (B.1.167)	-	C13551T, A13689T (E83D)
8	67	Kidney transplant, arterial hypertension, hypercholesterolemia	no	no	BNB 10d	RDV 10d	July 2021	Delta (B.1.167)	G15910T	C15237T, G15910T

9	64	Mantle lymphoma in complete remission	yes	No	DEX 10d, TCZ, BNB, anakinra	RDV 20d, TEC, IVM + plasma	August 2021	Delta (B.1.167)	-	C15952A (L838I)
---	----	---------------------------------------	-----	----	-----------------------------	----------------------------	-------------	-----------------	---	-----------------

3 ^aR-CHOP is a chemotherapy composed by the combination of rituximab, cyclophosphamide, hydroxidaunorubicine, oncovin and prednisone

4 Abbreviations: ICU intensive care unit, LPV lopinavir, RTV ritonavir, RDV remdesivir, HCQ hydroxichloroquine, AZM Azithromycin, TEC teicoplanin, IVM ivermectin, TCZ tocilizumab, BNB

5 baricitinib, DEX dexamethasone, CTX cyclophosphamide, PDN prednisone, CORT other corticoids.

6

7